Expertise in
20
conditions

Dr. Monika D. Joshi

Oncology
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 
Offers Telehealth
Expertise in
20
conditions
The Milton S. Hershey Medical Center
500 University Dr, 
Hershey, PA 

Overview

Monika Joshi is an Oncologist practicing medicine in Hershey, Pennsylvania.

Dr. Joshi is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 82 peer reviewed articles and participating in 10 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Penn State Health St. Joseph
Penn State Health Lancaster Medical Center
Milton S Hershey Medical Center
Penn State Health Holy Spirit Medical Center
Upmc Pinnacle Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

The Milton S. Hershey Medical Center
500 University Dr, Hershey, PA 17033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Enrollment Status: Terminated
Publish Date: November 27, 2024
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Enrollment Status: Terminated
Publish Date: July 01, 2022
Intervention Type: Drug
Study Phase: Phase 1
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Guadecitabine, Durvalumab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

82 Total Publications

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.
Journal: JCO oncology advances
Published: September 01, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Jonathan Bernstein is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Bernstein is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Spontaneous Urticaria (CSU), Hemophilia A, Mast Cell Activation Syndrome (MCAS), and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-6585
Languages Spoken:
English, Cantonese
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Ma is an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Ma is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Bone Marrow Aspiration. Dr. Ma is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-6585
Languages Spoken:
English
See accepted insurances

Chandra Belani is an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Belani is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Frequently Asked Questions about Dr. Monika D. Joshi

How do I make an appointment with Dr. Monika D. Joshi?

You can book an appointment with Dr. Monika D. Joshi by calling their office at 800-243-1455. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Monika D. Joshi a top-rated expert for Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Monika D. Joshi is classified as an Elite expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Monika D. Joshi specialize in?

While Dr. Monika D. Joshi is a Oncology, they have specific expertise in Bladder Cancer, Urothelial Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Monika D. Joshi participate in research or clinical trials?

Yes. Dr. Monika D. Joshi has published 82 articles and abstracts on conditions like Bladder Cancer. You can view a list of Dr. Monika D. Joshi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Monika D. Joshi accept my insurance?

Dr. Monika D. Joshi accepts most major insurance plans, including Aetna and Avalon Health Care. We recommend calling the office directly at 800-243-1455 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Joshi's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile